2-Amino-3-(methylamino)propanoic acid (BMAA) bioavailability in the primate

  title={2-Amino-3-(methylamino)propanoic acid (BMAA) bioavailability in the primate},
  author={M. Duncan and S. Markey and B. Weick and Philip G. Pearson and I. Kopin},
  journal={Neurobiology of Aging},
  • M. Duncan, S. Markey, +2 authors I. Kopin
  • Published 1992
  • Biology, Medicine
  • Neurobiology of Aging
  • 2-Amino-3-(methylamino)-propanoic acid (BMAA) is a low potency excitatory amino acid present in the cycad plant that has been proposed as a factor in the high incidence of amyotrophic lateral sclerosis-parkinsonism dementia (ALS-PD) in the western Pacific region. We employed stable isotopic forms of BMAA to assess the oral bioavailability of this compound in cynomolgous monkeys (n = 3). The stable isotope labeled BMAA ([15N]-BMAA) was injected i.v. at the same time that the unlabeled compound… CONTINUE READING
    33 Citations
    Does α-Amino-β-methylaminopropionic Acid (BMAA) Play a Role in Neurodegeneration?
    • 72
    • PDF
    Metabolism of the neurotoxic amino acid β-N-methylamino-L-alanine in human cell culture models.
    • 1
    A critical review of the postulated role of the non-essential amino acid, β-N-methylamino-L-alanine, in neurodegenerative disease in humans
    • N. Chernoff, D. Hill, +9 authors W. Winnik
    • Biology, Medicine
    • Journal of toxicology and environmental health. Part B, Critical reviews
    • 2017
    • 32
    Assessment of non‐derivatized &bgr;‐N‐methylamino‐l‐alanine (BMAA) neurotoxin in free form in urine of patients with nonspecific neurological symptoms
    • 5
    • Highly Influenced


    2-amino-3-(methylamino)-propanoic acid (BMAA) pharmacokinetics and blood-brain barrier permeability in the rat.
    • 86
    Guam ALS/parkinsonism-dementia: a long-latency neurotoxic disorder caused by "slow toxin(s)" in food?
    • P. Spencer
    • Medicine
    • The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques
    • 1987
    • 116
    • PDF